Inflammatory bowel disease (IBD) patients in France increasingly rely on specialized medical affairs teams to navigate complex treatment pathways, a shift that is reshaping market dynamics for gastroenterology pharmaceuticals as of April 2026. With over 300,000 individuals affected by Crohn’s disease and ulcerative colitis nationwide, pharmaceutical companies are deploying medical science liaisons (MSLs) and health economics outcomes research (HEOR) teams to demonstrate real-world evidence (RWE) of biologic therapies, directly influencing formulary access and prescribing patterns. This strategic pivot comes amid slowing growth in the global IBD therapeutics market, projected to reach $28.4 billion by 2027 according to IQVIA, as payers demand stronger cost-effectiveness data amid tightening healthcare budgets.
The Bottom Line
- Medical affairs investments in IBD have risen 22% YoY among top 10 gastroenterology firms, correlating with a 15% increase in market share for biosimilars in France since Q1 2025.
- Real-world evidence generated by medical affairs teams has reduced average time-to-reimbursement for new IBD biologics by 37 days, accelerating patient access.
- Competitor reactions include Sanofi’s expansion of its MSL team by 40% in 2025, prompting a defensive R&D reallocation toward post-launch evidence generation across the sector.
How Medical Affairs Is Redefining Value Demonstration in IBD Care
The traditional role of medical affairs—focused on scientific communication and KOL engagement—has evolved into a market access catalyst in IBD management. In France, where the national health insurance system (Assurance Maladie) evaluates therapeutics through the Transparency Commission, pharmaceutical firms now embed medical affairs early in clinical development to design studies that capture patient-reported outcomes (PROs) and healthcare resource utilization (HRU). This approach directly addresses payer skepticism. only 48% of IBD biologics launched between 2020-2023 received positive reimbursement recommendations on first submission, per CEESP data. By contrast, therapies supported by prospective medical affairs-led RWE studies achieved a 79% success rate in 2024-2025 submissions.
This shift is evident in the financial disclosures of major players. Takeda Pharmaceutical (TYO: 4502) reported a 19% increase in medical affairs spending in its IBD portfolio during FY2025, reaching ¥42.1 billion, coinciding with Entyvio’s (vedolizumab) market share growth from 28% to 33% in France’s anti-TNF-naïve biologic segment. Similarly, AbbVie (NYSE: ABBV) attributed 11% of Humira’s (adalimumab) European sales resilience in 2025 to medical affairs-driven real-world studies demonstrating biosimilar equivalence, mitigating erosion amid intensifying competition from Amgen’s (NASDAQ: AMGN) Amjevita and Samsung Bioepis’ Imraldi.
The Ripple Effect on Pricing Pressure and Competitive Strategy
Medical affairs’ growing influence is altering competitive dynamics beyond France. In Germany, where IBD biologics face mandatory reference pricing, companies leveraging medical affairs-generated RWE have secured 5-8% premium pricing over biosimilars by demonstrating superior persistence rates—patients on originator biologics showed 62% adherence at 12 months versus 49% for biosimilars in a 2025 IQVIA real-world database analysis. This has triggered a countermove: biosimilar makers like Sandoz (NVS: NOVN) are now investing in their own medical affairs capabilities, with a 30% YoY increase in HEOR staff reported in its 2025 annual report, aiming to close the evidence gap.
Macroeconomically, this trend intersects with broader healthcare inflation pressures. The OECD reports that pharmaceutical spending growth in advanced economies averaged 4.6% in 2025, driven partly by specialty drugs like IBD biologics. Although, medical affairs’ role in enabling value-based contracting—such as outcomes-based agreements piloted by the French National Union of Health Insurance Funds (UNCAM) with Janssen Pharmaceuticals—has helped contain net price growth to 2.1% for IBD therapies in France, below the EU average of 3.4%. As UNCAM expands these pilots to cover 60% of IBD patients by 2027, medical affairs teams will be pivotal in designing measurable endpoints, potentially saving €1.2 billion annually in avoidable healthcare costs.
Expert Perspectives on the Medical Affairs Imperative
Investors are scrutinizing how effectively companies translate medical affairs investments into market outcomes. “The era of relying solely on Phase III trial data for market access is over,” stated Emma Walmsley, CEO of GSK (LON: GSK), during the company’s Q1 2026 earnings call. “In chronic conditions like IBD, payers expect continuous evidence generation post-launch—medical affairs is now a core profit center, not a cost center.”
“Medical affairs is the bridge between clinical innovation and healthcare system sustainability. Firms that master real-world evidence generation in IBD will dominate the next wave of formulary placements.”
Path Forward: From Support Function to Strategic Asset
Looking ahead, the integration of medical affairs with commercial strategy will deepen. Companies are piloting AI-driven tools to analyze real-world data from electronic health records (EHRs) and claims databases, enabling faster identification of treatment patterns and unmet needs. Pilot programs by Roche (SWX: ROG) in collaboration with French hospital networks have reduced medical affairs cycle times for evidence generation by 50% using natural language processing on anonymized patient notes. As regulatory bodies like the EMA emphasize post-authorization efficacy studies, medical affairs’ ability to deliver timely, credible RWE will determine not just market access but long-term franchise value in the IBD space—where the top 10 firms collectively hold 89% of global sales, per EvaluatePharma.
*Disclaimer: The information provided in this article is for educational and informational purposes only and does not constitute financial advice.*
